▎ 摘　　要

NOVELTY - Use of an injectable hydrogel in the preparation of medicine for early-stage osteonecrosis of femoral head (ONFH) based on regulating vessel-associated osteoclast, where the injectable hydrogel is a sodium alginate/hyaluronic acid/glucono-δ-lactone injectable hydrogel loaded with a graphene oxide-polyethylenimine-miR7b (GO-PEI-miR7b) overexpression gene vector, is claimed. USE - The injectable hydrogel is used in the preparation of medicine for early-stage ONFH by regulating vessel-associated osteoclast, inhibiting the differentiation and fusion of vessel-associated osteoclast into bone-associated osteoclast, resisting bone-associated osteoclast osteophagic ability, promoting or retaining vessel-associated osteoclast, promoting bone formation, promoting angiogenesis and promoting H-type angiogenesis coupled with bone formation to treat early ONFH (all claimed). ADVANTAGE - The injectable hydrogel has a suitable gelation time, improved mechanical properties and slow-release function of the gene vector and protects and increases the number of vessel-associated osteoclast.